Morbidity of Cushing’s Syndrome and Impact of Treatment

• Autores: Susan M. Webb Youdale, Elena Valassi
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 47, Nº. 2, 2018 (Ejemplar dedicado a: Cushing's Syndrome), págs. 299-311
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chronic exposure to endogenous glucoc orticoid (GC) excess in patients with Cushing’s syndrome (CS) is associated with a cluster of complications, which negatively impact morbidity and mortality, including the metabolic syndrome, car- diovascular events, muscle weakness, bone fractures, neurocognitive impairment, and psychiatric disorders.

    1 Resolution of hypercortisolism after successful treat- ment does not lead to complete clinical remission, owing to the irreversible effects of previous hormone excess on many GC-sensitive tissues.

    2 Residual psycho- physical morbidity in “cured” CS makes their recovery slow and incomplete, and severely affects health-related quality of life (HRQoL) even in the long term after control of cortisol excess.

    3